Advertisement

PRRT with Radiolabeled Peptides: Indications, Procedures, and Results

  • Ettore Seregni
  • Alice Lorenzoni
Chapter

Abstract

Peptide receptor radionuclide therapy (PRRT) is an effective and usually well-tolerated treatment for unresectable or metastatic neuroendocrine tumors expressing somatostatin receptors. The two radiopharmaceuticals most commonly used for PRRT are 90Y-DOTATOC and 177Lu-DOTATATE which have been demonstrated to provide effective tumor response and symptom relief and have positive impact on survival. Chronic side effects on the kidneys and bone marrow are generally mild. Future perspectives include combinations with innovative therapeutic agents or the use of alpha-emitting radionuclide to improve PRRT efficacy.

Keywords

Peptide receptor radionuclide therapy (PRRT) Neuroendocrine tumor 90Y/177Lu-DOTATOC-DOTATATE 

References

  1. 1.
    Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014;28(9):749–56, 758.Google Scholar
  2. 2.
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458–511.CrossRefPubMedGoogle Scholar
  4. 4.
    Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O’Connor JM, Raymond E. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother Pharmacol. 2015;75(6):1099–114.CrossRefPubMedGoogle Scholar
  6. 6.
    van der Zwan WA, Bodei L, Mueller-Brand J, et al. GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172(1):R1–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Strosberg J, El-Haddad G, Wolin E, NETTER-1 Trial Investigators, et al. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Volkert WA, Hoffman TJ. Thrapeutic radiopharmaceuticals. Chem Rev. 1999;99:2269–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.CrossRefPubMedGoogle Scholar
  11. 11.
    Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17(3):313–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-termtoxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Sansovini M, Severi S, Ambrosetti A, et al. Treatment with the radiolabelled somatostatin analog Lu- DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97:347–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754–62.CrossRefPubMedGoogle Scholar
  16. 16.
    De Keizer B, van Aken MO, Feelders RA, et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008;35:749e55.CrossRefGoogle Scholar
  17. 17.
    Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5e19.Google Scholar
  18. 18.
    Gupta SK, Singla S, Bal C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 2012;27:593.CrossRefPubMedGoogle Scholar
  19. 19.
    Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9.CrossRefPubMedGoogle Scholar
  20. 20.
    Jamar F, Barone R, Mathieu I, et al. (86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)ea phase 1 clinical study: pharmacokinetics,biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510.CrossRefPubMedGoogle Scholar
  21. 21.
    Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847.CrossRefPubMedGoogle Scholar
  22. 22.
    Brabander T, Teunissen JJ, Van Eijck CH, et al. Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2016;30(1):103–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Kim SJ, Pak K, Koo PJ, Kwak JJ, Chang S. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(13):1964–70.CrossRefPubMedGoogle Scholar
  24. 24.
    Khan S, Krenning EP, van Essen M, et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52(9):1361–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43(3):441–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55(8):1248–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Nuclear MedicineFondazione IRCCS Istituto Nazionale TumoriMilanItaly

Personalised recommendations